|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Importance of adequate immunosuppressive therapy for the recovery of patients with 'life-threatening' severe exacerbation of chronic hepatitis B显示文摘AIM: Hepatitis B virus (HBV) re-activation often occurs spontaneously or after withdrawal of immunosuppressive therapy in patients with chronic hepatitis B. Severe exacerbation, sometimes developing into fulminant hepatic failure, is at high risk of mortality. The efficacy of corticosteroid therapy in 'clinically severe' exacerbation of chronic hepatitis B has not been well demonstrated. In this study we evaluated the efficacy of early introduction of high-dose corticosteroid therapy in patients with lifethreatening severe exacerbation of chronic hepatitis B.METHODS: Twenty-two patients, 14 men and 8 women,were defined as 'severe' exacerbation of chronic hepatitis B using uniform criteria and enrolled in this study. Eleven patients were treated with corticosteroids at 60 mg or more daily with or without anti-viral drugs within 10 d after the diagnosis of severe disease ('early high-dose'group) and 11 patients were either treated more than 10 d or untreated with corticosteroids ('non-early high-dose'group).RESULTS: Mean age, male-to-female ratio, mean prothrombin time (PT) activity, alanine transaminase (ALT)level, total bilirubin level, positivity of HBeAg, mean IgMHBc titer, and mean HBV DNA polymerase activity did not differ between the two groups. Ten of 11 patients of the 'early high-dose' group survived, while only 2 of 11 patients of the 'non-early high-dose' group survived (P<0.001). During the first 2 wk after the introduction of corticosteroids, improvements in PT activities and total bilirubin levels were observed in the 'early high-dose'group. Both ALT levels and HBV DNA polymerase levels fell in both groups.CONCLUSION: The introduction of high-dose corticosteroid can reverse deterioration in patients with 'clinically lifethreatening' severe exacerbation of chronic hepatitis B,when used in the early stage of illness. | Keiichi Fujiwara Osamu Yokosuka Hiroshige Kojima Tatsuo Kanda Hiromitsu Saisho Hiroyuki Hirasawa Hiroshi Suzuki | 2005 | World Journal of Gastroenterology2005，11，8： | 20 |
| 2 | β-cell dysfunction: Its critical role in prevention and management of type 2 diabetes显示文摘Type 2 diabetes(T2DM) is characterized by insulin resistance and β-cell dysfunction. Although, in contrast to type 1 diabetes, insulin resistance is assumed to be a major pathophysiological feature of T2 DM, T2 DM never develops unless β-cells fail to compensate insulin resistance. Recent studies have revealed that a deficit of β-cell functional mass is an essential component of the pathophysiology of T2 DM, implying that β-cell deficit is a common feature of both type 1 and type 2 diabetes. β-cell dysfunction is present at the diagnosis of T2 DM and progressively worsens with disease duration. β-cell dysfunction is associated with worseningof glycemic control and treatment failure; thus, it is important to preserve or recover β-cell functional mass in the management of T2 DM. Since β-cell regenerative capacity appears somewhat limited in humans, reducing β-cell workload appears to be the most effective way to preserve β-cell functional mass to date, underpinning the importance of lifestyle modification and weight loss for the treatment and prevention of T2 DM. This review summarizes the current knowledge on β-cell functional mass in T2 DM and discusses the treatment strategy for T2 DM. | Yoshifumi Saisho | 2015 | World Journal of Diabetes2015，6，1： | 20 |
| 3 | Effect of Clostridium butyricum on fecal flora in Helicobacter pylori eradication therapy显示文摘AIM: To investigate the effect of probiotic bacterium,Clostridium butyricum MIYAIRI 588 strain (CBM) on the changes of the fecal flora in Helicobacter pylori(H pylori)treatment.METHODS: Thirty-five patients with gastric or duodenal ulcers positive for Hpylori were randomized either to 1 wk amoxicillin, clarithromycin, lansoprazole (Group 1) or to the same regimen supplemented with CBM 7 dahead of the triple therapy (Group 2). Stool samples were collected before and 2, 4, 7, 15, and 22 d after the starting eradication therapy, and were examined intestinal flora. Patients were required to keep a diary record of their condition. RESULTS: Obligate anaerobes decreased significantly on d 2, 4, 8 and 15 in Group 1. On the other hand, they did not decrease significantly in Group 2. The Escherichiacoli was dominant bacterium in Enterobacteriaceae, butthat was replaced by other species such as Klebsiella and Enterobacter after eradication in Group 1. The change was suppressed in Group 2. Abdominal symptoms were less frequent in Group 2 than in Group 1.CONCLUSION: The combined use of CBM reduced the changes in the intestinal flora and decreased the incidence of gastrointestinal side effects. | Izumi Shimbo Taketo Yamaguchi Takeo Odaka Kenichi Nakajima Akinori Koide Hidehiko Koyama Hiromitsu Saisho | 2005 | World Journal of Gastroenterology2005，11，47： | 18 |
| 4 | Consensus of primary care in acute pancreatitis in Japan显示文摘在日本的尖锐胰腺炎的发生正在增加并且每百万张人口从 187 ~ 347 个盒子。盒子命运是 0.2% 为对温和中等,并且 9.0% 为在在 2003 的日本的严重尖锐胰腺炎。在日本的胰腺炎的专家做了与尖锐胰腺炎在病人的早管理集中于实际方面的这个文件。尖锐胰腺炎和严厉层化的正确诊断应该为尖锐胰腺炎的诊断用标准在所有病人被做并且多,因素得分系统尽早由胰的难处理的疾病的研究委员会求婚了。与尖锐胰腺炎诊断的所有病人应该在医院里被管理。血压监视,脉搏和呼吸率,体温,时时尿的体积,和血氧饱和水平在如此的病人的管理是必要的。早精力旺盛的静脉内的水和具有最前的重要性稳定循环动力学。有鸦片剂的足够的疼痛地势也是重要的。在严重尖锐胰腺炎,在一个早阶段的抗菌素的预防静脉内的管理被推荐。一旦尖锐胰腺炎的诊断被证实,朊酶禁止者的管理应该被开始。如果没有肠塞痛并且胃肠的流血的清楚的症状,从早舞台用非肠道的营养喂的肠内的联合被推荐。有严重尖锐胰腺炎的病人应该尽早被转移到 ICU 执行象朊酶的连续地区性的动脉的注入那样的特殊措施禁止者和抗菌素,和连续牙齿过敏过滤。日本政府为难处理的疾病作为关于措施的研究的工程之一为严重尖锐胰腺炎盖住医疗保健开销。 | Makoto Otsuki Masahiko Hirota Shinju Arata Masaru Koizumi Shigeyuki Kawa Terumi Kamisawa Kazunori Takeda Toshihiko Mayumi Motoji Kitagawa Tetsuhide Ito Kazuo Inui Tooru Shimosegawa Shigeki Tanaka Keisho Kataoka Hiromitsu Saisho Kazuichi Okazaki Yosikazu Kuroda Norio Sawabu Yoshifumi Takeyama | 2006 | World Journal of Gastroenterology2006，12，21： | 9 |
| 5 | Doppler study of hepatic vein in cirrhotic patients:Correlation with liver dysfunction and hepatic hemodynamics显示文摘AIM: To elucidate the significance of Doppler measurements of hepatic vein in cirrhotic patients and to correlate with liver dysfunction and hepatic hemodynamics. METHODS: One hundred patients with liver cirrhosis and 60 non-cirrhotic controls were studied. Doppler waveforms were obtained from right hepatic vein and flow velocity measured during quiet respiration. Doppler measurements were also obtained from portal trunk, right portal vein and proper hepatic artery. RESULTS: Hepatic vein waveforms were classified into three classical patterns. Flat waveform was uncommon. Mean hepatic vein velocity was significantly higher in cirrhotic patients (12.7 ± 6.4 vs 5.1 ± 2.1 and 6.2 ± 3.2 cm/s; P < 0.0001). The poorer the grade of cirrhosis, the higher was the mean velocity. Maximum forward velocity was never greater than 40 cm/s in controls. Degree of ascites was found to be highly correlated with mean velocity. “Very high” group (≥ 20 cm/s) presented clinically with moderate to massive ascites. Correlations between right portal flow and mean velocity was significant (P < 0.0001, r = 0.687). CONCLUSION: Doppler waveforms of hepatic vein, which is independent of liver dysfunction, should be obtained during normal respiration. Mean hepatic vein velocity reflects the change in hepatic circulation associated with progression of liver cirrhosis. It can be used as a new parameter in the assessment of liver cirrhosis. | KC Sudhamshu Shoiichi Matsutani Hitoshi Maruyama Taro Akiike Hiromitsu Saisho | 2006 | World Journal of Gastroenterology2006，12，36： | 8 |
| 6 | Effect of lamivudinein in BeAg-positive chronic hepatitis B: Discordant effect on HBeAg and HBV DNA according to pretreatment ALT level显示文摘AIM: To clarify differences in antiviral effect of the drug in patients with different ALT levels, we examined the changes in HBV markers in patients with high or low ALT levels with or without lamivudine treatment. METHODS: Thirty-seven HBeAg-positive patients were studied. Ten patients with ALT levels higher than 200 IU/L (group 1) and 8 patients with ALT below 200 IU/L (group 2) were treated orally with 100 mg/d of lamivudine. As untreated control, 9 patients with ALT above 200 IU/L (group 3) and 10 patients with ALT below 200 IU/L (group 4) were examined. ALT level, HBeAg/HBeAb status, and HBV DNA level were examined monthly for 11.9±0.4 mo.RESULTS: The ALT level normalized in all 10 patients of group 1, 7/8 of group 2, 4/9 of group 3, and 1/10 of group 4 within 6 mo (groups 1 vs 2, P = NS; groups 1 vs 3, P = 0.002; groups 1vs 4, P<0.0001). HBV DNA fell below the detection limit in all 10 patients of group 1, 7/8 of group 2, 0/9 of group 3, and 0/10 of group 4 within 6 mo (groups 1 vs 2, P = NS). HBeAg became seronegative in 7/10 patients of group 1, 1/8 of group 2, 3/9 of group 3, and 0/10 of group 4 within 12 mo (groups 1 vs2, P= 0.02;groups 1 vs 3, P = NS).CONCLUSION: Our data suggest that HBeAg-positive patients with higher ALT levels can be considered good candidates for lamivudine therapy, probably because lamivudine accelerates the natural seroconversion of HBeAg, accompanied by HBV DNA loss, in these patients. | Tomoko Kurihara Fumio Imazeki Osamu Yokosuka Kenichi Fukai Tatsuo Kanda Shigenobu Kawai Hiromitsu Saisho | 2005 | World Journal of Gastroenterology2005，11，22： | 5 |
| 7 | Significance of a novel sucrose permeability test using serum in the diagnosis of early gastric cancer显示文摘AIM: To investigate the usefulness of sucrose permeability test using serum in the diagnosis of gastric diseases, with special reference to early gastric cancer (EGC).METHODS: A total of 63 subjects, including 11patients with gastric ulcer, 20 patients with gastric cancer (13, early; 7, advanced) and 32 healthy controls,were studied. Blood and urine samples were collected repeatedly for 5 h before and after the sucrose loading.Sucrose levels were measured by a newly developed enzymatic method.RESULTS: Serum sucrose levels started to increase15 min after loading, and peaked at 60 min in the gastric disease groups. The levels for gastric ulcer, EGC and advanced gastric cancer (AGC) at 60 min were significantly higher than that in the healthy controls(26.9±2.4, 34.4±5.0, and 71.8±15.6 vs 7.9±0.7 mol/L,respectively, P<0.01). The cut-off level set at 15.4 mol/L(60 min) offered the best distinction between EGC patients and healthy controls; and the sensitivity and specificity were 92.3% and 93.8%, respectively, while those of the urine method were 76.9% and 93.8%,respectively.CONCLUSIONS: The gastric permeability test using serum is reliable for the detection of EGC, and this test can provide results much earlier than the conventional urine method. This test may offer a useful alternative to more invasive tests for EGC. | Tadayuki Shishido Taketo Yamaguchi Takeo Odaka Masanori Seimiya Hiromitsu Saisho Fumio Nomura | 2005 | World Journal of Gastroenterology2005，11，44： | 5 |
| 8 | Severe hypercholesterolemia associated with primary biliary cirrhosis in a 44-year-old Japanese woman显示文摘A 44-year-old woman developed jaundice and was diagnosed as stage II of primary biliary cirrhosis (PBC). She showed a severely high total cholesterol level. This article focuses on atypical presentations of PBC and the need to test the total cholesterol level of PBC patients. | Tatsuo Kanda Osamu Yokosuka Hiroshige Kojima Fumio Imazeki Keiich Nagao Ichiro Tatsuno Yasushi Saito Hiromitsu Saisho | 2004 | World Journal of Gastroenterology2004，10，17： | 2 |
| 9 | Signaling pathway of insulin-like growth factor-Ⅱ as a target of molecular therapy for hepatoblastoma显示文摘AIM: To address the possibility that insulin-like growth factor (IGF)-Ⅱ is a growth factor and its signaling pathway so as to develop a molecular therapy for hepatoblastoma. METHODS: Huh-6 and HepG2, human hepatoblastoma cell lines, were used. IGF-Ⅱ was added to the medium deprived of serum. Western blot analysis was performed to clarify the expression of IGF-I receptor (IGF-IR). Inhibitors of IGF-IR (piclopodophyllin, PPP), phosphatidyl-inositol (PI) 3-kinase (LY294002 and Wortmannin), or mitogen-activated protein (MAP) kinase (PD98059) were added to unveil the signaling pathway of IGF-Ⅱ. Cells were analyzed morphologically with hematoxylin-eosin staining to reveal the mechanism of suppression of cell proliferation.RESULTS: IGF-Ⅱ stimulated cells proliferated to 2.7 (269% ± 76%) (mean ± SD) (Huh-6) and 2.1 (211% ± 85%) times (HepG2). IGF-IR was expressed in Huh-6 and HepG2. PPP suppressed the cell number to 44% ± 11% (Huh-6) and 39% ± 5% (HepG2). LY294002 and Wortmannin suppressed the cell number to 30% ± 5% (Huh-6), 44% ± 0.4% (HepG2), 49% ± 1.0% (Huh-6) and 46% ± 1.1% (HepG2), respectively. PD98059 suppressed the cell number to 33% ± 11% for HepG2 but not for Huh-6. When cell proliferation was prohibited, many Huh-6 and HepG2 cells were dead with pyknotic or fragmented nuclei, suggesting apoptosis.CONCLUSION: IGF-Ⅱ was shown to be a growth factor of hepatoblastoma via IGF-I receptor and PI3 kinase which were good candidates for target of molecular therapy. | Minoru Tomizawa Hiromitsu Saisho | 2006 | World Journal of Gastroenterology2006，12，40： | 2 |
| 10 | Different behaviors of microbubbles in the liver: time-related quantitative analysis of two ultrasound contrast agents, Levovist and Definity 显示文摘 | Maruyama H Matsutani S Saisho H | 2004 | Ultrasound Med Biol2004，30，8： | 1 |
| 11 | Diagnostic imaging for pancreatic cancer:computed tomography, magnetic resonance imaging,and positron emission tomography显示文摘 | Saisho H Yamaguchi T | 2004 | Pancreas2004，28，3： | 1 |
| 12 | Betacell dysfunction and its clinical significance in gosmional diabetes显示文摘 | Saisho Y Miyakoshi K Tanaka M | 2010 | Endocr J2010，57，11： | 1 |
| 13 | The copper/zinc ratio in patients with hepatocellular carcinoma显示文摘 | Masaaki Ebara Hiroyuki Fukuda Hiromitsu Saisho | 2003 | Journal of Gastroenterology2003，，1： | 1 |
| 14 | Glycated albumin toglycated hemoglobin ratio reflects postprandial glucoseexcursion and relates to beta cell function in both type 1 andtype 2 diabetes显示文摘 | Saisho Y Tanaka K Abe T | 2011 | Diabetol Int2011，2，3： | 1 |
| 15 | Grey-scale contrast enhancement in rabbit liver with DMP115 at different acoustic power levels显示文摘 | Maruyama H Matsutani S Saisho H | 2000 | Ultrasound Med Biol2000，26，9： | 1 |
| 16 | The copper/zinc ratio in patients with hepatocellular carcinoma显示文摘 | Ebara M Fukuda H Saisho H | 2003 | Journal of Gastroenterology2003，38，1： | 1 |
| 17 | p62/SQSTM1 cooperates with Parkin for perinuelear clustering of depolarized mitochondria显示文摘 | Okatsu K Saisho K Shimanuki M | 2010 | Genes Cells2010，15，8： | 1 |
| 18 | ATP synthesis steady-state level inhibitorsas well as respiratory inhibitiors increase of alternative oxidase mRNA in Arabidosis thaliana 显示文摘 | Saisho D Nakazono M Tsutsumi N Hirai A | 2001 | J Plant Physiol2001，35，： | 1 |
| 19 | Irradiation with ultrasound of low output intensity increased chemosensitivity of subcutaneous solid tumors to an anti-cancer agent显示文摘 | Tomizawa M Ebara M Saisho H | 2001 | Cancer Lett2001，173，： | 1 |
| 20 | Sonographic shift of hypervascular liver tumor on blood pool harmonic images with definity:Time-related changes of contrast-enhanced appearance in rabbit VX2 tumor under extra-low acoustic power显示文摘 | Maruyama H Matsutani S Saisho H | 2005 | Eur J Radiol2005，56，1： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员